Asthma patients who smoke experience more severe symptoms as well as airflow limitation, and benefit less from treatment with inhaled corticosteroids (ICS) compared with non-smoking asthmatics \[[@CR1]\]. Additionally, smoking is associated with small airways dysfunction (SAD) \[[@CR2]\]. The small airways, defined by a diameter ≤ 2 mm contribute to the resistance in the airways of patients with obstructive airways disease \[[@CR3]\]. This has a clinical impact since small airways can be inflamed in asthma and hence narrowed \[[@CR4]\]. We hypothesized that smokers and ex-smokers with asthma would benefit more from extrafine than non-extrafine particle ICS. However, our OLiVIA-study showed that extrafine and non-extrafine particle ICS were equally effective in improving small airways function in current and ex-smokers with asthma \[[@CR5]\]. This outcome might be ascribed to the fact that the presence of SAD was not an inclusion criterion in our study. Therefore, we performed a post-hoc analysis to investigate whether current and ex-smoking asthmatics with SAD show a better clinical response to extrafine compared to non-extrafine particle ICS. Next, we investigated which clinical parameters, apart from the presence of SAD, predict a favorable response to extrafine and non-extrafine particle ICS.

The OLiVIA-study was an open-label, randomized, three-way crossover, two-center study, comparing two-week treatment with extrafine hydrofluoroalkane (HFA)-beclomethasone 200 μg b.i.d. (QVAR) to non-extrafine HFA-beclomethasone 400 μg b.i.d. (Clenil) and non-extrafine HFA-fluticasone 250 μg b.i.d. (Flixotide) \[[@CR5]\]. The primary outcome was the change in airway hyperresponsiveness (AHR) to small particle adenosine, expressed as the provocative dose of adenosine causing a 20% drop in FEV~1~ (forced expiratory volume at 1 s) from baseline to post-treatment (ΔPD~20~). Small particle adenosine is a provocative agent that acts indirectly via the release of mediators from inflammatory cells. It was chosen rather than methacholine as it is a more sensitive measurement to detect improvement in AHR after treatment with ICS in patients with asthma \[[@CR6]\].

Since there is no clearly defined golden standard for SAD, we applied various parameters next to the PD~20~ adenosine, i.e. parameters of spirometry, body plethysmography, impulse oscillometry (IOS) and multiple breath nitrogen washout (MBNW). We used cut-off values for SAD parameters as follows: forced expiratory flow between 25 and 75% of forced vital capacity \[FEF~25--75~\] \< lower limit of normal (LLN) from spirometry; ratio of residual volume to total lung capacity \[RV/TLC\] \> upper limit of normal (ULN) from body plethysmography; difference between resistance at 5 Hz and 20 Hz \[R~5~-R~20~\] \> 0.1 kPa sL^− 1^ from IOS \[[@CR7]\]; and ventilation heterogeneity of the acinar structures \[S~acin~\] and conductive airways \[S~cond~\] \> ULN from MBNW \[[@CR8]\]. These measurements were taken at the baseline visit after an ICS washout period of four to six weeks. The presence of SAD was defined as: at least 3 out of 5 criteria fulfilled when all lung function measurements were performed, or with 2 out of 3 criteria if MBNW was not carried out, which was the case in 8 patients.

We performed a two-sided paired t-test or Wilcoxon test to assess the difference in ΔPD~20~ adenosine after treatment with extrafine compared to non-extrafine particle ICS in patients with SAD and patients without SAD. PD~20~ values were log~2~-transformed prior to analyses. To investigate the difference in ΔPD~20~ between patients with SAD and without SAD within one treatment group, we performed a student t-test or Mann-Whitney test. Next, we explored which baseline variables (i.e. demographics, small and large function measures, presence of atopy and blood leukocyte counts) were associated with ΔPD~20~ adenosine after extrafine and non-extrafine particle ICS treatment using univariate linear regression analysis. We finally performed multivariate linear regression analyses for each treatment type to identify independent clinical predictors for ΔPD~20~ including age, sex, smoking status, numbers of neutrophils and eosinophils, and completed with those variables showing a trend towards association with ΔPD~20~ (*p* \< 0.1) in the univariate analysis. We allowed a maximum of 7 variables to be included in the multivariate model. The variables in this final model were selected based on the following criteria: (1) the variable changed regression coefficients (B) \> 10%, (2) the model had highest total explained variance (R^2^), and (3) the model preferably included the highest number of subjects.

We analyzed 43 asthma patients (22 smokers and 21 ex-smokers), 42% being male, with mean (standard deviation (SD)) age 45 (12.6) years, FEV~1~ 83 (14.5) % predicted, and PD~20~ 2.69 (3.41) mg. Baseline characteristics of the study population are presented in Additional file [1](#MOESM1){ref-type="media"}: Table S1. At baseline, we found that SAD was present in 18 (42%) patients (see Additional file [1](#MOESM1){ref-type="media"}: Table S2). Asthma patients with and without SAD had similar response in PD~20~ adenosine to extrafine (QVAR) and non-extrafine particle ICS treatments (Clenil and Flixotide) (Fig. [1](#Fig1){ref-type="fig"}; and Additional file [1](#MOESM1){ref-type="media"}: Table S3).Fig. 1Change in PD~20~ adenosine from baseline to post-treatment with QVAR, Clenil and Flixotide in patients with and without small airways dysfunction (SAD). Each line depicts a subject while the bold line depicts the mean change in PD~20~ adenosine in response to the treatment. PD~20~: provocative dose of small particle adenosine causing a 20% drop in forced expiratory volume at 1 s (FEV~1~)

Results of the univariate linear regression analyses are presented in Additional file [1](#MOESM1){ref-type="media"}: Table S4. Multivariate linear regression analyses (Table [1](#Tab1){ref-type="table"}) showed that no parameters of SAD were associated with treatment response to either small or large particle ICS. Lower numbers of blood neutrophils were associated with a larger increase in PD~20~ adenosine, independently from the level of blood eosinophils, in patients treated with QVAR, Clenil and Flixotide (all *p* \< 0.05). Higher blood eosinophils were also associated with a larger increase in PD~20~ adenosine in patients treated with Flixotide (*p* \< 0.05). Finally, younger age tended to be associated with a larger increase in PD~20~ adenosine after using Clenil (*p* = 0.05).Table 1Multivariate linear regression analysis of baseline variables with change in airway hyperresponsiveness to small particle adenosine (ΔPD~20~) as dependent variable in patients treated with QVAR, Clenil and FlixotideBaseline predictorsB95% CI*p*-valueR^2^ΔPD~20~ QVARAge, years−0.10− 0.06; 0.040.7030.64Sex, male/ female0.41−0.78; 1.600.485Current smoking, yes/no−0.47−1.87; 0.930.493Blood neutrophils, 10^9^/L−0.55−1.00; − 0.090.020Blood eosinophils, 10^9^/L2.81−0.48; 6.090.090FEV~1~, % predicted0.04−0.01; 0.090.090LCI at 2.5%−0.30− 0.69; 0.080.117ΔPD~20~ ClenilAge, years−0.06− 0.12; 0.000.0500.48Sex, male/ female0.80−0.42; 2.030.192Current smoking, yes/no−0.95−2.33; 0.430.170Blood neutrophils, 10^9^/L−0.61−1.04; − 0.180.006Blood eosinophils, 10^9^/L3.04−0.06; 6.150.054FEV~1~, % predicted0.03−0.01; 0.070.180ΔPD~20~ FlixotideAge, years−0.03−0.08; 0.020.1810.60Sex, male/ female0.85−0.25; 1.960.125Current smoking, yes/no−0.33−1.51; 0.850.573Blood neutrophils, 10^9^/L−0.78−1.13; −0.430.000Blood eosinophils, 10^9^/L3.530.88; 6.170.011FEV~1~, % predicted0.002−0.04; 0.040.937RV/TLC, % predicted−0.03−0.06; 0.0040.089B: regression coefficients; CI: Confidence Intervals; R^2^: total explained variance; ΔPD~20~: the change from baseline to post-treatment in the provocative dose of small particle adenosine causing a 20% drop in FEV~1~; FEV~1~: forced expiratory volume in 1 s; LCI: lung clearance index; and RV/TLC: the ratio of residual volume to total lung capacity

We did not confirm our hypothesis that current and ex-smoking asthmatics with SAD had a better treatment response to QVAR compared to Clenil and Flixotide. In line with previous reports on better clinical effects of ICS in asthmatics with eosinophilia \[[@CR9]--[@CR11]\], we show that higher blood eosinophils are associated with a less severe AHR after treatment with non-extrafine particle ICS (Flixotide). Of interest, our study shows that higher blood neutrophils are associated with more severe AHR after treatment with both extrafine and non-extrafine particle ICS in smokers and ex-smokers with asthma, independently from the level of blood eosinophils. Findings by Telenga et al. support that lower blood neutrophils are associated with an increase in FEV~1~ after 2-week ICS-therapy \[[@CR11]\]. Taken together, we find that higher blood neutrophils are associated with less clinical ICS-response in smokers and ex-smokers with asthma. However, our data (Additional file [1](#MOESM1){ref-type="media"}: Figure S1) do not clearly show a cut-off value for eosinophilia or neutrophilia that can be used in clinical practice to define a positive response. Future studies have to assess whether this change in inflammation in peripheral blood is reflected by changes in the small and larger airways.

A strength of the study is that we defined SAD by cut-off levels applying multiple measurement techniques including spirometry, body plethysmography, impulse oscillometry and multiple breath nitrogen washout. A limitation is the relatively small sample size of patients with SAD and non-SAD which limits the power of the study and raises the risk of type I error. However, a post-hoc power analysis indicated that we had a sufficient number of patients to detect a difference of one doubling dose increase in PD~20~ adenosine between patients with and without SAD. With a standard deviation of one doubling dose, β = 0.8 and α = 0.05, we would need 16 patients per group while in our study, 18 patients with and 23 patients without SAD were investigated. Further studies with larger sample sizes would provide a clearer picture of SAD in smokers and ex-smokers with asthma. Another possible limitation is that we treated for two weeks which may have been too short to improve SAD.

In conclusion, we show that smoking and ex-smoking asthmatics with and without SAD have a similar response to small particle adenosine after treatment with either extrafine or non-extrafine particle ICS. These findings suggest that clinicians may not need to consider SAD in order to decide whether current- and ex-smoking asthmatics would benefit preferentially from treatment with extrafine rather than non-extrafine particle ICS. Of importance, we find that lower blood neutrophils is a favorable predictor of ICS response, independent from the level of blood eosinophils.
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ΔPD~20~

:   The change from baseline to post-treatment in the provocative dose of small particle adenosine causing a 20% drop in forced expiratory volume in 1 s (FEV~1~)

AHR

:   Airway hyperresponsiveness

AX

:   The area under curve of reactance

BMI

:   Body mass index

CFC

:   Chlorofluorocarbon

FEF~25--75~

:   Forced expiratory flow between 25 and 75% of FVC

FVC

:   Forced vital capacity

F~res~

:   Resonance frequency

HFA

:   Hydrofluoroalkane

ICS

:   Inhaled corticosteroids

LCI

:   Lung clearance index

LLN

:   Lower limit of normal

R~5~-R~20~

:   The difference between resistance at 5 Hz and 20 Hz

RV

:   Residual volume

RV/TLC

:   The ratio of residual volume to total lung capacity

SAD

:   Small airways dysfunction

S~acin~

:   Ventilation heterogeneity of the acinar structures

S~cond~

:   Ventilation heterogeneity of the conductive airways

TLC

:   Total lung capacity

ULN

:   Upper limit of normal

X~5~

:   The reactance at 5 Hz
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